Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Capricor Therapeutics (CAPR) Equity Average (2016 - 2025)

Capricor Therapeutics (CAPR) has 15 years of Equity Average data on record, last reported at $94.4 million in Q3 2025.

  • For Q3 2025, Equity Average rose 136.74% year-over-year to $94.4 million; the TTM value through Sep 2025 reached $94.4 million, up 136.74%, while the annual FY2024 figure was $84.0 million, 388.73% up from the prior year.
  • Equity Average reached $94.4 million in Q3 2025 per CAPR's latest filing, down from $116.3 million in the prior quarter.
  • Across five years, Equity Average topped out at $136.6 million in Q1 2025 and bottomed at $471753.5 in Q3 2023.
  • Average Equity Average over 5 years is $40.6 million, with a median of $28.0 million recorded in 2022.
  • Peak YoY movement for Equity Average: crashed 97.24% in 2023, then surged 8354.34% in 2024.
  • A 5-year view of Equity Average shows it stood at $34.1 million in 2021, then plummeted by 60.04% to $13.6 million in 2022, then fell by 23.51% to $10.4 million in 2023, then skyrocketed by 926.85% to $106.9 million in 2024, then fell by 11.64% to $94.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were $94.4 million in Q3 2025, $116.3 million in Q2 2025, and $136.6 million in Q1 2025.